Structurally dissecting APOBEC3's for HIV-1 restriction and beyond
从结构上剖析 APOBEC3 的 HIV-1 限制及其他限制
基本信息
- 批准号:10082374
- 负责人:
- 金额:$ 70.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:Active SitesAddressAntiviral AgentsBindingBiological AssayBiophysicsCatalytic DomainCell NucleusChemicalsChemistryCollaborationsComplementComplexCryo-electron tomographyCryoelectron MicroscopyCrystallizationCytidine DeaminaseDNADNA VirusesDataDeaminationDependovirusDinucleoside PhosphatesDouble Stranded DNA VirusDrug DesignEngineeringEnsureEnzymatic BiochemistryEnzymesEpitopesFamilyFutureGenomeGenomicsGoalsHIVHIV-1Head CancerHepatitis B VirusHerpesviridaeHumanHuman PapillomavirusImmune systemKnowledgeLaboratoriesLettersLibrariesMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of lungMalignant neoplasm of urinary bladderMutationNatural ImmunityNeck CancerNuclearNucleic AcidsOligonucleotidesPan GenusPositioning AttributeRNAReagentResearchRetrotransposonRetroviridaeRoentgen RaysRoleSeriesSingle Stranded DNA VirusSiteSourceSpecificityStructureSubstrate SpecificitySurfaceSystemTherapeuticTranslatingVariantViral GenomeVirionVirus Diseasesadaptive immunitychemotherapydesignexperienceinhibitor/antagonistinterdisciplinary approachintermolecular interactionmalignant breast neoplasmmolecular modelingoverexpressionparticlepathogenstructural biologystructured datatherapeutic developmenttumorubiquitin-protein ligasevif Gene Productsvirology
项目摘要
Structurally dissecting APOBEC3s for HIV-1 restriction and beyond
The human immune system protects us against pathogens but can cause problems when
the system goes awry. Implicated in both innate and adaptive immunity, the AID/APOBEC
family of enzymes are cytidine deaminases with differential roles of still limited
understanding. A subset of APOBEC3s (A3s) were initially discovered to potently restrict
HIV-1, including A3G, A3F and A3H. These restrictive enzymes are so potent that HIV
evolved the “virion infectivity factor” protein Vif to counter this restriction by hijacking an E3
ubiquitin ligase and specifically targeting A3s for degradation. Subsequent research has
revealed that A3’s ability to respond and restrict viral infection is by inducing
hypermutations in the viral genome, which is not limited to HIV but extends to other
retroviruses and retrotransposons. A3s also restrict DNA viruses, including nuclear
replicating ssDNA viruses such as adeno-associated virus and dsDNA viruses such as
hepatitis B virus, herpes viruses and HPV. However, A3 activity can be a double-edged
sword. If not properly regulated, DNA-editing APOBECs that also have access to the
nucleus can deaminate self-genomes, potentially instigating cancer. When overexpressed,
A3A, A3B and A3H have been described as a major endogenous source for mutations in
various types of human cancer, such as breast, bladder, head and neck, cervical, and lung
cancer. We hypothesize that A3s have unrealized therapeutic potentials, both as anti-viral
targets through reactivating the natural anti-HIV function by blocking Vif binding and as
targets for chemotherapy to restrict the genome diversity within tumors. In this proposal we
are leveraging our complementary strengths through a multi-disciplinary approach combining
structural biology, biophysics, enzymology, chemistry and virology, to characterize the
molecular interactions and differential specificities of A3s to nucleic acids and HIV-1 Vif, which
will provide epitopes that once characterized will be target sites for future therapeutic
development.
结构解剖APOBEC 3用于HIV-1限制及其他
人体免疫系统保护我们免受病原体的侵害,但当
系统就会出错AID/APOBEC与先天免疫和适应性免疫有关,
酶的家族是胞苷脱氨酶,其在细胞内的不同作用仍然有限。
认识最初发现APOBEC 3(A3)的一个子集可以有效限制
HIV-1,包括A3 G、A3 F和A3 H。这些限制性酶是如此强大,
进化出了“病毒体感染因子”蛋白Vif,通过劫持E3蛋白来对抗这种限制。
泛素连接酶和特异性靶向A3进行降解。随后的研究
揭示了A3的反应和限制病毒感染的能力是通过诱导
病毒基因组中的超突变,这不仅限于HIV,还扩展到其他
逆转录病毒和逆转录转座子。A3还限制DNA病毒,包括核病毒。
复制型ssDNA病毒如腺相关病毒和dsDNA病毒如
B型肝炎病毒、疱疹病毒和HPV。然而,A3活性可能是一把双刃剑,
剑如果没有适当的监管,DNA编辑APOBECs也可以访问
细胞核可以使自身基因组脱氨基,潜在地诱发癌症。当过度表达时,
A3 A、A3 B和A3 H已被描述为在哺乳动物中突变的主要内源性来源。
各种类型的人类癌症,如乳腺癌、膀胱癌、头颈癌、宫颈癌和肺癌
癌我们假设A3具有未实现的治疗潜力,无论是作为抗病毒,
通过阻断Vif结合重新激活天然抗HIV功能,
限制肿瘤内基因组多样性的化疗靶点。在本提案中,我们
通过多学科的方法,
结构生物学,生物物理学,酶学,化学和病毒学,以表征
A3对核酸和HIV-1 Vif的分子相互作用和差异特异性,
将提供一旦表征将成为未来治疗靶点的表位
发展
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Celia A. Schiffer其他文献
Non-canonical pattern recognition of a pathogen-derived metabolite by a nuclear hormone receptor identifies virulent bacteria in emC. elegans/em
核激素受体对病原体衍生代谢物的非典型模式识别在秀丽隐杆线虫中鉴定出有毒细菌
- DOI:
10.1016/j.immuni.2023.01.027 - 发表时间:
2023-04-11 - 期刊:
- 影响因子:26.300
- 作者:
Nicholas D. Peterson;Samantha Y. Tse;Qiuyu Judy Huang;Khursheed A. Wani;Celia A. Schiffer;Read Pukkila-Worley - 通讯作者:
Read Pukkila-Worley
Activation Of Interferon Regulatory Factors Revealed By The Crystal Structure Of Dimeric IRF-5
- DOI:
10.1016/j.bpj.2008.12.3070 - 发表时间:
2009-02-01 - 期刊:
- 影响因子:
- 作者:
William E. Royer;Weijun Chen;Suvana S. Lam;Hema Srinath;Zhaozhao Jiang;John J. Correia;Celia A. Schiffer;Katherine A. Fitzgerald;Kai Lin - 通讯作者:
Kai Lin
Using Molecular Dynamics to Investigate Substrate Recognition and Co-evolution in HIV-1 Protease
- DOI:
10.1016/j.bpj.2008.12.3129 - 发表时间:
2009-02-01 - 期刊:
- 影响因子:
- 作者:
Aysegul Ozen;Turkan Haliloglu;Celia A. Schiffer - 通讯作者:
Celia A. Schiffer
Accounting for molecular mobility in structure determination based on nuclear magnetic resonance spectroscopic and X-ray diffraction data.
基于核磁共振波谱和 X 射线衍射数据的结构测定中的分子迁移率。
- DOI:
- 发表时间:
1994 - 期刊:
- 影响因子:0
- 作者:
W. V. Gunsteren;R. Brunne;P. Gros;René C. van Schaik;Celia A. Schiffer;A. Torda - 通讯作者:
A. Torda
Tetrameric Assembly of the Oncogenic C-Terminal Binding Proteins
- DOI:
10.1016/j.bpj.2018.11.380 - 发表时间:
2019-02-15 - 期刊:
- 影响因子:
- 作者:
William E. Royer;Andrew G. Bellesis;Anne M. Jecrois;Brendan J. Hilbert;Martin M. Dcona;Steven R. Grossman;Celia A. Schiffer - 通讯作者:
Celia A. Schiffer
Celia A. Schiffer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Celia A. Schiffer', 18)}}的其他基金
Integration of Evolution to Avoid Resistance in Structure Based Drug Design
整合进化以避免基于结构的药物设计中的耐药性
- 批准号:
10388034 - 财政年份:2020
- 资助金额:
$ 70.23万 - 项目类别:
Integration of Evolution to Avoid Resistance in Structure Based Drug Design
整合进化以避免基于结构的药物设计中的耐药性
- 批准号:
10437865 - 财政年份:2020
- 资助金额:
$ 70.23万 - 项目类别:
Design of Protease Inhibitors to Target HTLV-1
针对 HTLV-1 的蛋白酶抑制剂的设计
- 批准号:
10201509 - 财政年份:2020
- 资助金额:
$ 70.23万 - 项目类别:
Integration of Evolution to Avoid Resistance in Structure Based Drug Design
整合进化以避免基于结构的药物设计中的耐药性
- 批准号:
10642936 - 财政年份:2020
- 资助金额:
$ 70.23万 - 项目类别:
Integration of Evolution to Avoid Resistance in Structure Based Drug Design
整合进化以避免基于结构的药物设计中的耐药性
- 批准号:
10256048 - 财政年份:2020
- 资助金额:
$ 70.23万 - 项目类别:
Design of Protease Inhibitors to Target HTLV-1
针对 HTLV-1 的蛋白酶抑制剂的设计
- 批准号:
10057413 - 财政年份:2020
- 资助金额:
$ 70.23万 - 项目类别:
Structurally dissecting APOBEC3's for HIV-1 restriction
结构剖析 APOBEC3 的 HIV-1 限制
- 批准号:
9340247 - 财政年份:2016
- 资助金额:
$ 70.23万 - 项目类别:
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond
从结构上剖析 APOBEC3 的 HIV-1 限制及其他限制
- 批准号:
10682566 - 财政年份:2016
- 资助金额:
$ 70.23万 - 项目类别:
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond
从结构上剖析 APOBEC3 的 HIV-1 限制及其他限制
- 批准号:
10461788 - 财政年份:2016
- 资助金额:
$ 70.23万 - 项目类别:
Structurally dissecting APOBEC3's for HIV-1 restriction
结构剖析 APOBEC3 的 HIV-1 限制
- 批准号:
9769778 - 财政年份:2016
- 资助金额:
$ 70.23万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 70.23万 - 项目类别:
Research Grant